O'Hara, Daniel Vincent and Bassi, Abhinav and Wilcox, Arlen and Jha, Vivekanand and Rathore, Vinay and D'Cruz, Sanjay and Snelling, Thomas L. and Jones, Mark and Totterdell, James and Bangi, Ashpak and Jain, Manish Kumar and Pollock, Carol and Burrell, Louise and Fox, Gregory and Jones, Cheryl and Kotwal, Sradha and Omar, Sharifah Faridah Syed and Jardine, Meg and CLARITY 2 0 trial investigators, - (2024) Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial. BMJ Open, 14 (10). e081790. ISSN 2044-6055, DOI https://doi.org/10.1136/bmjopen-2023-081790.
Full text not available from this repository.Abstract
Objective To determine whether a chemokine receptor type 2 antagonist, DMX-200 (repagermanium), in combination with an angiotensin receptor blocker, candesartan, improves clinical outcomes in people with COVID-19. Design Prospective, multicentre, double-blind, placebo-controlled trial. Setting Ten acute care hospitals in India. Participants Adults <65 years old intended for hospital admission with moderate/severe COVID-19 disease (respiratory rate >= 24 breaths per minute or oxygen saturation <= 93% on room air). Intervention DMX-200 120 mg two times per day, or placebo, on background of titratable candesartan commencing at 4 mg two times per day, for 28 days. Main outcome measures The primary endpoint was COVID-19 disease severity on a modified WHO Clinical Progression Scale (WHO scale) on day 14. Secondary outcomes included the WHO scale at days 28, 60, 90 and 180; intensive care unit (ICU) admission, respiratory failure or death within 28 days; length of hospitalisation; and requirement for ventilatory support or dialysis. Results Between December 2021 and August 2022, 518 people were screened, with 49 randomised to DMX-200 or placebo on a background of candesartan. The study was terminated early due to recruitment barriers, including an external requirement to restrict enrolment to adults <65 years old, contributing to a 91% screen failure rate. The median WHO Clinical Progression Scale (WHO scale) score at day 14 for both groups was 1 (IQR 1-1), indicating most participants were discharged with no limitations on activities by this time. Formal comparison was not performed due to the small sample size. One participant receiving DMX-200 died of COVID-19 disease progression. No participants required ICU admission, ventilation or dialysis. Median length of hospitalisation in both groups was 6 days (IQR 6-7 days). WHO scale scores were similar at 28, 60, 90 and 180 days. Conclusion Due to recruitment barriers, the study was unable to determine whether DMX-200 improves clinical outcomes in people with COVID-19.
| Item Type: | Article |
|---|---|
| Funders: | Dimerix Bioscience Pty Ltd., Australian Government Department of Industry, Innovation and Science, Royal Australian Society of Nephrology Jacquot Research Entry Scholarship, National Health & Medical Research Council (NHMRC) of Australia |
| Subjects: | R Medicine > R Medicine (General) |
| Divisions: | Faculty of Medicine > Medicine Department |
| Depositing User: | Ms. Juhaida Abd Rahim |
| Date Deposited: | 17 Feb 2025 04:11 |
| Last Modified: | 17 Feb 2025 04:11 |
| URI: | http://eprints.um.edu.my/id/eprint/47412 |
Actions (login required)
 |
View Item |
